Literature DB >> 12029573

Elevated intraocular levels of insulin-like growth factor I in a diabetic patient with acromegaly.

Gysbert van Setten1, K Brismar, P Algvere.   

Abstract

Growth factors have become increasingly associated with various events of vitreoretinal disease. In the presence of proliferative retinopathy, elevated levels of insulin growth factor I (IGF-I) have been demonstrated in the vitreous. IGF-I expression itself is regulated by growth hormone, a hormone that is involved in the pathogenesis of acromegaly. In the present paper we report on the detection of very high IGF-levels in the subretinal fluid of a patient with acromegaly who was operated for retinal detachment. With a very sensitive RIA assay we found a four-fold elevation of the serum levels of IGF-I (604 ng/ml) and a high level of IGF-1 in the subretinal fluid (13 ng/ml). It is concluded that acromegaly may lead to an overexpression of IGF-I not only seen as increased concentrations in serum and vitreous, but in the subretinal space as well. This study emphasizes the need for further investigation of growth factor presence in pathological cavities, such as the subretinal space during retinal detachments.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12029573     DOI: 10.1076/orbi.21.2.161.7186

Source DB:  PubMed          Journal:  Orbit        ISSN: 0167-6830


  10 in total

1.  Evaluation of macular and peripapillary choroidal thickness, macular volume and retinal nerve fiber layer in acromegaly patients.

Authors:  Serpil Yazgan; Dilek Arpaci; Haci Ugur Celik; Irem Isik
Journal:  Int Ophthalmol       Date:  2017-05-15       Impact factor: 2.031

2.  Retina ganglion cell/inner plexiform layer and peripapillary nerve fiber layer thickness in patients with acromegaly.

Authors:  Muhammed Şahin; Alparslan Şahin; Faruk Kılınç; Harun Yüksel; Zeynep Gürsel Özkurt; Fatih Mehmet Türkcü; Zafer Pekkolay; Hikmet Soylu; İhsan Çaça
Journal:  Int Ophthalmol       Date:  2016-08-04       Impact factor: 2.031

3.  Chorio-retinal thickness measurements in patients with acromegaly.

Authors:  G Pekel; F Akin; M S Ertürk; S Acer; R Yagci; M C Hıraali; E N Cetin
Journal:  Eye (Lond)       Date:  2014-09-19       Impact factor: 3.775

4.  Cornea in acromegalic patients as a possible target of growth hormone action.

Authors:  A Ciresi; M C Amato; D Morreale; G Lodato; A Galluzzo; C Giordano
Journal:  J Endocrinol Invest       Date:  2010-07-22       Impact factor: 4.256

5.  Advanced proliferative diabetic retinopathy and macular edema in acromegaly: a case report and literature review.

Authors:  Akiko Yuno; Akemi Ikota; Shigeki Koizumi; Yasuo Mashio; Hiroko Imaizumi; Yutaka Sawamura; Akira Shimatsu
Journal:  Diabetol Int       Date:  2022-01-25

6.  Evaluation of central corneal and central retinal thicknesses and intraocular pressure in acromegaly patients.

Authors:  Sefika Burcak Polat; Nagihan Ugurlu; Reyhan Ersoy; Oguzhan Oguz; Necati Duru; Bekir Cakir
Journal:  Pituitary       Date:  2014-08       Impact factor: 4.107

7.  Comparing acromegalic patients to healthy controls with respect to intraocular pressure, central corneal thickness, and optic disc topography findings.

Authors:  Emine Sen; Yasemin Tutuncu; Ufuk Elgin; Melike Balikoglu-Yilmaz; Dilek Berker; F Nur Aksakal; Faruk Ozturk; Serdar Guler
Journal:  Indian J Ophthalmol       Date:  2014-08       Impact factor: 1.848

8.  Diabetic retinopathy in acromegaly.

Authors:  Said Azzoug; Farida Chentli
Journal:  Indian J Endocrinol Metab       Date:  2014-05

9.  Comparing two acromegalic patients with respect to central corneal thickness, intraocular pressure, and tear insulin-like growth factor levels before and after treatment.

Authors:  Kan Emrah; Kilic Kan Elif; Okuyucu Ali
Journal:  Indian J Ophthalmol       Date:  2015-09       Impact factor: 1.848

10.  Evaluation of Peripapillary Microcirculation in Patients with Acromegaly.

Authors:  Mine Karahan; Atilim Armagan Demirtas; Leyla Hazar; Sedat Ava; Zafer Pekkolay; Ugur Keklikci
Journal:  Beyoglu Eye J       Date:  2021-12-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.